Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Satellos Bioscience (MSCLF)
OTHER OTC:MSCLF
RESEARCH TOOLSreports
Satellos Bioscience (MSCLF) Stock Price & Analysis
18 Followers
MSCLF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.22 - $0.58
Previous Close$0.35
Volume45.50K
Average Volume (3M)17.64K
Market Cap
$39.57M
Enterprise Value$39.53M
Total Cash (Recent Filing)C$44.26K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta7.46
Next Earnings
Aug 26, 2024EPS Estimate
-$0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding112,791,658
10 Day Avg. Volume13,670
30 Day Avg. Volume17,645
Standard Deviation0.24
R-Squared0.12
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.57
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$0.88Price Target Upside151.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Satellos Bioscience News
PremiumCompany Announcements
Satellos Bioscience Advances to Clinical Trials with SAT-3247
PremiumCompany Announcements
Satellos Bioscience’s Breakthrough in DMD Treatment
PremiumCompany Announcements
Satellos CEO Joins PPMD Panel, Preps for Clinical Trial
PremiumCompany Announcements
Satellos Forms Board for DMD Drug Trials
PremiumCompany Announcements
Satellos Bioscience Shareholders Back Key ResolutionsPremiumCompany Announcements
Satellos Bioscience Prepares for Phase 1 Trials
Options Prices
Currently, No data available
---
Ownership Overview
40.88% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
59.12% Public Companies and
Individual Investors
MSCLF FAQ
What was Satellos Bioscience’s price range in the past 12 months?
Satellos Bioscience lowest stock price was $0.22 and its highest was $0.58 in the past 12 months.
What is Satellos Bioscience’s market cap?
Currently, no data Available
When is Satellos Bioscience’s upcoming earnings report date?
Satellos Bioscience’s upcoming earnings report date is Aug 26, 2024 which is in 38 days.
How were Satellos Bioscience’s earnings last quarter?
Satellos Bioscience released its earnings results on May 14, 2024. The company reported -$0.044 earnings per share for the quarter, missing the consensus estimate of -$0.037 by -$0.007.
Is Satellos Bioscience overvalued?
According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued.
Does Satellos Bioscience pay dividends?
Satellos Bioscience does not currently pay dividends.
What is Satellos Bioscience’s EPS estimate?
Satellos Bioscience’s EPS estimate is -$0.04.
How many shares outstanding does Satellos Bioscience have?
Satellos Bioscience has 112,791,660 shares outstanding.
What happened to Satellos Bioscience’s price movement after its last earnings report?
Satellos Bioscience reported an EPS of -$0.044 in its last earnings report, missing expectations of -$0.037. Following the earnings report the stock price went down -2.941%.
Which hedge fund is a major shareholder of Satellos Bioscience?
Currently, no hedge funds are holding shares in MSCLF
---
Satellos Bioscience Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.88 (151.43% Upside)
$0.88 (151.43% Upside)
Insider Transactions
Bought Shares
Worth $31.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.66%
12-Months-Change
Fundamentals
Return on Equity
-115.63%
Trailing 12-Months
Asset Growth
442.82%
Trailing 12-Months
Company Description
Satellos Bioscience
iCo Therapeutics, Inc. engages in the business of identification, development and commercialization of drug candidates for the treatment of sight- and life-threatening diseases. Its products include iCo-008 and oral AmpB delivery system. The company was founded by Andrew J. Rae, John G. Clement and William John Meekison on February 15, 2005 and is headquartered in Vancouver, CA.
---
MSCLF Stock 12 Month Forecast
Average Price Target
$0.88
▲(151.43% Upside)
Technical Analysis
Best Analysts Covering MSCLF
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-6.00%
reiterated a buy rating 7 days ago
Copying Arthur He CFA's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -6.00% per trade.
---